OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
Abstract Background Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-022-02264-9 |
| _version_ | 1828091214567571456 |
|---|---|
| author | Jefferson Antonio Buendía Diana Guerrero Patiño Erika Fernanda Lindarte |
| author_facet | Jefferson Antonio Buendía Diana Guerrero Patiño Erika Fernanda Lindarte |
| author_sort | Jefferson Antonio Buendía |
| collection | DOAJ |
| description | Abstract Background Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. Methods A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1–6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. Results The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. Conclusion In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines. |
| first_indexed | 2024-04-11T06:09:43Z |
| format | Article |
| id | doaj.art-6b1c6d507e7d44e6a0dc7edb02aee1fb |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-11T06:09:43Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-6b1c6d507e7d44e6a0dc7edb02aee1fb2022-12-22T04:41:22ZengBMCBMC Pulmonary Medicine1471-24662022-12-012211710.1186/s12890-022-02264-9OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysisJefferson Antonio Buendía0Diana Guerrero Patiño1Erika Fernanda Lindarte2Research Group in Pharmacology and Toxicology “INFARTO”, Department of Pharmacology and Toxicology, University of AntioquiaResearch Group in Pharmacology and Toxicology “INFARTO”, Department of Pharmacology and Toxicology, University of AntioquiaResearch Group in Pharmacology and Toxicology “INFARTO”, Department of Pharmacology and Toxicology, University of AntioquiaAbstract Background Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. Methods A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1–6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. Results The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. Conclusion In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.https://doi.org/10.1186/s12890-022-02264-9Health economicsPublic healthHealthcareColombiaCorticosteroids |
| spellingShingle | Jefferson Antonio Buendía Diana Guerrero Patiño Erika Fernanda Lindarte OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis BMC Pulmonary Medicine Health economics Public health Healthcare Colombia Corticosteroids |
| title | OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full | OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_fullStr | OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full_unstemmed | OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_short | OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_sort | om 85 bv in pediatric recurrent respiratory tract infections a cost utility analysis |
| topic | Health economics Public health Healthcare Colombia Corticosteroids |
| url | https://doi.org/10.1186/s12890-022-02264-9 |
| work_keys_str_mv | AT jeffersonantoniobuendia om85bvinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis AT dianaguerreropatino om85bvinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis AT erikafernandalindarte om85bvinpediatricrecurrentrespiratorytractinfectionsacostutilityanalysis |